StockData
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. (AMLX) income statement

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$26.62−0.90 (-3.27%)

Close on Nov 18, 2026Market cap $2.97BP/E –Yield –

Amylyx Pharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-61.6%

Financial strength

Current ratio
12.12
Debt to equity
–
Debt to assets
–
Cash to current liabilities
233.2%

Valuation

P/E ratio
–
Price to sales
–
Price to book
12.40
Dividend yield
–

See a number that looks wrong?